Chronic Pulmonary Aspergillosis: An Update on Diagnosis and Treatment

被引：44

作者：

Godet, Cendrine ^{[1
]}

Philippe, Bruno ^{[2
]}

Laurent, Francois ^{[3
,4
]}

Cadranel, Jacques ^{[5
,6
]}

机构：

[1] CHU La Miletrie, Dept Infect Dis, Poitiers, France

[2] Rene Dubos Hosp, Dept Pneumol, Pontoise, France

[3] Univ Hosp Bordeaux, Haut Leveque Hosp, Dept Diagnost & Therapeut Imaging, Bordeaux, France

[4] Univ Victor Segalen, Bordeaux, France

[5] Hop Tenon, AP HP, Serv Pneumol, FR-75970 Paris 20, France

[6] Univ Paris 06, Fac Med Pierre & Marie Curie, Paris, France

来源：

RESPIRATION | 2014年 / 88卷 / 02期

关键词：

Chronic pulmonary aspergillosis; Aspergilloma; Antifungal treatment; SURGICAL-TREATMENT; CLINICAL CHARACTERISTICS; GALACTOMANNAN ANTIGEN; PRACTICE GUIDELINES; FUNGAL-INFECTIONS; SEVERE HEMOPTYSIS; CHRONIC CAVITARY; ITRACONAZOLE; SPECTRUM; MANAGEMENT;

D O I：

10.1159/000362674

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

Chronic pulmonary aspergillosis (CPA) affects individuals with non-systemic or mildly systemic immunodepression or altered pulmonary integrity due to underlying disease. It has been reported with a variety of clinical and radiological patterns. The condition should be distinguished from simple aspergilloma and allergic bronchopulmonary aspergillosis as well as invasive aspergillosis in severely immunocompromised patients. CPA generally requires long-term antifungal treatment and surgery may be considered. Life-threatening haemoptysis may be prevented by bronchial arteriography with embolisation. However, currently there are no documented treatment recommendations for CPA. This review provides an up-to-date practical overview of this condition, including a comprehensive update on diagnosis and management. (C) 2014 S. Karger AG, Basel

引用

页码：162 / 174

页数：13

共 50 条

[31] Clinical features and diagnosis of chronic pulmonary aspergillosis in Chinese patients
Hou, Xiaomeng
Zhang, Hong
Kou, Lei
Lv, Wei
Lu, Jingjing
Li, Ji
MEDICINE, 2017, 96 (42)
[32] The Aspergillus lateral flow assay for the diagnosis of chronic pulmonary aspergillosis
不详
MEDICAL MYCOLOGY, 2022, 60 (SUPP 1) : 269 - 270
[33] Impact of treatment duration on recurrence of chronic pulmonary aspergillosis
Im, Yunjoo
Jhun, Byung Woo
Kang, Eun-Suk
Koh, Won-Jung
Jeon, Kyeongman
JOURNAL OF INFECTION, 2021, 83 (04) : 490 - 495
[34] Antifungal Treatment for Japanese Patients with Chronic Pulmonary Aspergillosis
Takazono, Takahiro
Saito, Yoshiyuki
Tashiro, Masato
Yoshida, Masataka
Takeda, Kazuaki
Ide, Shotaro
Iwanaga, Naoki
Hosogaya, Naoki
Sakamoto, Noriho
Mukae, Hiroshi
Izumikawa, Koichi
INFECTIOUS DISEASES AND THERAPY, 2025, 14 (01) : 245 - 259
[35] Treatment of chronic pulmonary aspergillosis by voriconazole in nonimmunocompromised patients
Camuset, Juliette
Nunes, Hilario
Dombret, Marie-Christine
Bergeron, Anne
Henno, Priscilla
Philippe, Bruno
Dauriat, Gaelle
Mangiapan, Gilles
Rabbat, Antoine
Cadranel, Jacques
CHEST, 2007, 131 (05) : 1435 - 1441
[36] Voriconazole treatment for subacute invasive and chronic pulmonary aspergillosis
Sambatakou, Helen
Dupont, Bertrand
Lode, Hartmut
Denning, David W.
AMERICAN JOURNAL OF MEDICINE, 2006, 119 (06):
[37] Clinical characteristics and treatment outcomes of chronic pulmonary aspergillosis
Jhun, Byung Woo
Jeon, Kyeongman
Eom, Jung Seop
Lee, Ji Hyun
Suh, Gee Young
Kwon, O. Jung
Koh, Won-Jung
MEDICAL MYCOLOGY, 2013, 51 (08) : 811 - 817
[38] Chronic pulmonary aspergillosis
Denning, D.
MYCOSES, 2015, 58 : 41 - 41
[39] Chronic pulmonary aspergillosis
Schweer, K. E.
Bangard, C.
Hekmat, K.
Cornely, O. A.
MYCOSES, 2014, 57 (05) : 257 - 270
[40] Role of serum procalcitonin in the diagnosis and monitoring of treatment response in treatment-naive subjects with chronic pulmonary aspergillosis
Sehgal, Inderpaul Singh
Dhooria, Sahajal
Sachdeva, Naresh
Rudramurthy, Shivaprakash M.
Prasad, Kuruswamy Thurai
Muthu, Valliappan
Aggarwal, Ashutosh Nath
Garg, Mandeep
Chakrabarti, Arunaloke
Agarwal, Ritesh
HELIYON, 2023, 9 (04)

← 1 2 3 4 5 →